View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2013	Jul. 24, 2013
Entity Information [Line Items]
Entity Registrant Name	MIMEDX GROUP, INC.
Entity Central Index Key	0001376339
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		96,374,784
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 4,193,583	$ 6,754,485
Accounts receivable, net	11,761,874	7,653,561
Inventory, net	4,220,284	3,022,784
Prepaid expenses and other current assets	1,351,948	657,961
Total current assets	21,527,689	18,088,791
Property and equipment, net of accumulated depreciation of $2,517,774 and $2,279,840, respectively	2,990,746	1,071,625
Goodwill	4,040,443	4,040,443
Intangible assets, net of accumulated amortization of $5,378,990 and $4,848,756, respectively	11,724,210	11,911,749
Deposits and other long term assets	0	70,000
Total assets	40,283,088	35,182,608
Current liabilities:
Accounts payable	1,837,711	1,251,684
Accrued compensation	2,974,709	2,753,237
Accrued expenses	1,075,916	990,697
Other current liabilities	252,343	75,154
Total current liabilities	6,140,679	5,070,772
Earn-out liability payable in MiMedx common stock	0	5,792,330
Convertible Senior Secured Promissory Notes, net	0	4,012,442
Other liabilities	1,250,866	299,762
Total liabilities	7,391,545	15,175,306
Commitments and contingencies	0	0
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $.001 par value; 130,000,000 shares authorized; 96,356,451 issued and 96,306,451 outstanding for 2013 and 88,423,169 issued and 88,373,169 outstanding for 2012	96,356	88,423
Additional paid-in capital	104,881,706	89,627,601
Treasury stock (50,000 shares at cost)	(25,000)	(25,000)
Accumulated deficit	(72,061,519)	(69,683,722)
Total stockholders' equity	32,891,543	20,007,302
Total liabilities and stockholders' equity	$ 40,283,088	$ 35,182,608

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
ASSETS
Property and equipment, net of accumulated depreciation	$ 2,517,774	$ 2,279,840
Intangible assets, net of accumulated amortization	$ 5,378,990	$ 4,848,756
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	130,000,000	130,000,000
Common stock, shares issued (in shares)	96,356,451	88,423,169
Common stock, shares outstanding (in shares)	96,306,451	88,373,169
Treasury stock, shares (in shares)	50,000	50,000

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues:
Net sales	$ 13,514,743	$ 4,884,256	$ 25,071,235	$ 8,590,064
Cost of sales	2,198,482	1,114,926	4,103,502	2,073,781
Gross margin	11,316,261	3,769,330	20,967,733	6,516,283
Operating expenses:
Research and development expenses	924,468	503,086	2,171,222	910,158
Selling, general and administrative expenses	10,868,372	3,049,783	19,237,384	5,687,052
Amortization of intangible assets	267,638	333,977	530,234	667,954
Operating income (loss)	(744,217)	(117,516)	(971,107)	(748,881)
Other income (expense), net
Amortization of debt discount	0	(472,749)	(1,328,439)	(783,226)
Interest expense, net	(13,172)	(153,804)	(27,976)	(305,614)
Income (loss) before income tax provision	(757,389)	(744,069)	(2,327,522)	(1,837,721)
Income tax provision	0	0	(50,275)	0
Net Income (loss)	$ (757,389)	$ (744,069)	$ (2,377,797)	$ (1,837,721)
Net income (loss) per common share - basic and diluted (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)
Weighted average shares outstanding - basic and diluted (in shares)	95,988,100	79,952,542	94,599,406	77,416,073

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) - 6 months ended Jun. 30, 2013 - USD ($)	Total	Convertible Preferred Stock Series A [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$ 20,007,302	$ 0	$ 88,423	$ 89,627,601	$ (25,000)	$ (69,683,722)
Balance (in shares) at Dec. 31, 2012		0	88,423,169
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,487,239	$ 0	$ 0	2,487,239	0	0
Exercise of stock options	$ 542,841	$ 0	$ 489	542,352	0	0
Exercise of stock options (in shares)	489,197	0	489,197
Exercise of warrants	$ 1,167,624	$ 0	$ 997	1,166,627	0	0
Exercise of warrants (in shares)		0	997,166
Common stock issued for 5% convertible note	$ 5,272,004	$ 0	$ 5,272	5,266,732	0	0
Common stock issued for 5% convertible note (in shares)	5,272,004	0	5,272,004
Common stock issued for earn-out liability	$ 5,792,330	$ 0	$ 1,175	5,791,155	0	0
Common stock issued for earn-out liability (in shares)	1,174,915	0	1,174,915
Net income (loss)	$ (2,377,797)	$ 0	$ 0	0	0	(2,377,797)
Balance at Jun. 30, 2013	$ 32,891,543	$ 0	$ 96,356	$ 104,881,706	$ (25,000)	$ (72,061,519)
Balance (in shares) at Jun. 30, 2013		0	96,356,451

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) (Parenthetical)	Jun. 30, 2013
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Convertible note percentage (in hundredths)	5.00%

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:
Net income (loss)	$ (2,377,797)	$ (1,837,721)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation	237,934	231,491
Amortization of intangible assets	530,234	667,954
Amortization of debt discount and deferred financing costs	1,328,439	783,226
Share-based compensation	2,487,239	1,086,200
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(4,108,313)	(2,054,414)
Inventory	(1,197,500)	(249,337)
Prepaid expenses	(721,223)	(127,559)
Other assets	70,000	0
Accounts payable	586,027	(372,938)
Accrued compensation	221,472	119,241
Accrued expenses	85,219	(84,939)
Accrued interest	(41,641)	232,107
Other liabilities	46,362	7,878
Net cash flows from operating activities	(2,853,548)	(1,598,811)
Cash flows from investing activities:
Purchases of equipment	(1,052,930)	(238,498)
Patent application costs	(342,695)	0
Net cash flows from investing activities	(1,395,625)	(238,498)
Cash flows from financing activities:
Proceeds from exercise of warrants	1,167,624	323,638
Proceeds from exercise of stock options	542,841	315,295
Repayment of convertible debt related to acquisition	0	(250,000)
Principal payments of equipment leases	(22,194)	(9,256)
Net cash flows from financing activities	1,688,271	379,677
Net change in cash	(2,560,902)	(1,457,632)
Cash and cash equivalents, beginning of period	6,754,485	4,112,326
Cash and cash equivalents, end of period	$ 4,193,583	$ 2,654,694

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included. Operating results for the six months ended June 30, 2013 and 2012, are not necessarily indicative of the results that may be expected for the fiscal year. The balance sheet at December 31, 2012, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2013. The Company operates in one business segment, Biomaterials, which includes the design, manufacture, and marketing of products and amnion tissue processing for a variety of surgical applications using the Company’s proprietary biomaterials—CollaFix™, HydroFix®, EpiFix® and AmnioFix®.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Significant Accounting Policies	6 Months Ended
Significant Accounting Policies	Jun. 30, 2013
Accounting Policies [Abstract]
Significant accounting policies	Significant Accounting Policies Please see Note 2 to our Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2012, for a description of all significant accounting policies. Reclassifications Certain items previously reported in financial statement captions have been reclassified to conform to the current financial statement presentation. These reclassifications did not affect total assets, total liabilities, and stockholders’ equity. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Accounts Receivable Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. The Company has $44,000 and $49,000 in the allowance for doubtful accounts as of June 30, 2013 and December 31, 2012, respectively. Actual customer collections could differ from estimates. The approximate provision during the six months ended June 30, 2013 was $27,000, and there were approximately $32,000 of write–offs during the same period. Inventories Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. Revenue Recognition The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilized distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The Company recorded approximately $281,000 and $107,000 for net sales returns provisions for the three months ended June 30, 2013 and 2012, respectively, and there were approximately $231,000 and $26,000 of charges against the provision during the three months ended June 30, 2013 and 2012, respectively. The Company recorded approximately $471,000 and $146,000 for net sales returns provisions for the six months ended June 30, 2013 and 2012, respectively, and there were approximately $397,000 and $26,000 of charges against the provision during the six months ended June 30, 2013 and 2012, respectively. Patent Costs The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $343,000 of patent costs during the first six months of 2013. There were not any patent costs capitalized for the six months ended June 30, 2012. Recent Accounting Pronouncements The Company considers the applicability and impact of all ASUs. For the six months ended June 30, 2013 and through the date of this report, all ASUs issued, effective and not yet effective, were assessed and determined to be either not applicable or are expected to have minimal impact on our financial position or results of operations.

Liquidity and Management's Plans	6 Months Ended
Liquidity and Management's Plans	Jun. 30, 2013
Liquidity and management's plans [Abstract]
Liquidity and management's plans	Liquidity and Management’s Plans As of June 30, 2013, the Company had approximately $4,194,000 of cash and cash equivalents. The Company reported total current assets of approximately $21,528,000 and current liabilities of approximately $6,141,000 as of June 30, 2013. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs, fund its planned investing activities for the next twelve months.

Inventories

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following items as of June 30, 2013 and December 31, 2012:



	June 30, 2013			December 31, 2012
Raw materials	$	270,441		$	233,747
Work in process	2,765,802			1,598,537
Finished goods	1,425,996			1,349,121
	4,462,239			3,181,405
Reserve for obsolescence	(241,955		)	(158,621		)
Inventory, net	$	4,220,284		$	3,022,784

Property and Equipment

6 Months Ended

Jun. 30, 2013

Property, Plant and Equipment [Abstract]

Property and equipment

Property and Equipment

Property and equipment consist of the following as of June 30, 2013 and December 31, 2012:



	June 30, 2013			December 31, 2012
Leasehold improvements	$	2,147,775		$	1,022,230
Lab and clean room equipment	1,901,219			1,887,645
Furniture and office equipment	903,433			431,563
Construction in progress	556,093			10,027
	5,508,520			3,351,465
Less accumulated depreciation	(2,517,774		)	(2,279,840		)
	$	2,990,746		$	1,071,625

Included in property and equipment is approximately $154,000 of capital leases. The corresponding liability is included in other liabilities in the accompanying consolidated balance sheet.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Intangible Assets and Royalty Agreement

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible assets and royalty agreement

Intangible Assets and Royalty Agreement

Intangible assets activity is summarized as follows:



	June 30, 2013								December 31, 2012
	Weighted Average Amortization Lives	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Impairment Adjustment			Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization:
License-Shriners Hsp for Children & USF Research (a)	10 years	$	996,000	$	(637,433	)	$	358,567	$	996,000	$	—		$	(587,633	)	$	408,367
License - SaluMedica LLC Spine Repair (b)	10 years	1,547,324		(1,547,324		)	—		2,399,000		(851,676		)	(1,547,324		)	—
License - Polyvinyl Alcohol Cryogel (c)	10 years	1,720,181		(1,287,824		)	432,357		2,667,000		(946,819		)	(1,223,561		)	496,620
Customer Relationships (d)	14 years	3,520,000		(628,572		)	2,891,428		3,520,000		—			(502,857		)	3,017,143
Supplier Relationships (d)	14 years	241,000		(43,036		)	197,964		241,000		—			(34,428		)	206,572
Patents & Know-How (d)	14 years	5,530,000		(987,500		)	4,542,500		5,530,000		—			(790,000		)	4,740,000
Micronized Processing Know-How (d)	14 years	2,160,000		(231,428		)	1,928,572		2,160,000		—			(154,286		)	2,005,714
Licenses/Permits (d)	3 years	13,000		(10,833		)	2,167		13,000		—			(8,667		)	4,333
Patent Application Cost ( e )	17 years	342,695		(5,040		)	337,655		—		—			—			—
		16,070,200		(5,378,990		)	10,691,210		17,526,000		(1,798,495		)	(4,848,756		)	10,878,749
Intangible assets not subject to amortization:
Trade Names/Trademarks (d)	indefinite	1,008,000		—			1,008,000		1,008,000		—			—			1,008,000
In-process Research & Development-Other (d)	indefinite	25,000		—			25,000		25,000		—			—			25,000
		$	17,103,200	$	(5,378,990	)	$	11,724,210	$	18,559,000	$	(1,798,495	)	$	(4,848,756	)	$	11,911,749

(a)

On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date). Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products.


(b)	License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value.

(c)

On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol hydrogel. The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date). The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales. On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement. As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000. In September 2012, the cost of the license was deemed to be impaired and reduced to its fair value. At June 30, 2013 and December 31, 2012, there are no additional amounts accrued for this obligation due to its contingent nature.


(d)	On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.

(e) Capitalized external legal and other registration costs in connection with internally developed tissue based patents.

Future Amortization Expense

Expected future amortization of intangible assets is as follows:



	Estimated Amortization Expense
Year ending December 31,	Estimated Amortization Expense
2013 (a)	$	535,266
2014	1,066,205
2015	1,044,151
2016	997,156
2017	906,960
Thereafter	6,141,472
	$	10,691,210


(a)	Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after June 30, 2013.

Long-Term Debt

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Long-Term Debt

The following table summarizes our long-term debt:



	June 30, 2013		December 31, 2012
$5M Convertible Senior Secured Promissory Notes including interest at 5% per annum payable quarterly through December 31, 2013, and an additional one time 5% interest charge payable on January 15, 2013 if not repaid by December 31, 2012, collateralized by a first priority lien shared equally with holder of the Convertible Line of Credit with Related Party in all of the patents and intellectual property owned by the Company subordinated to the Convertible Debt related to acquisition for Surgical Biologics intellectual property until repaid. (a)	$	—	$	5,313,645
Total debt	—		5,313,645
Less unamortized debt discount	—		(1,301,203		)
Less current portion	—		—
Long-term portion	$	—	$	4,012,442

(a) Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. On December 31, 2011, a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company's share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052 which was recorded as a debt discount and was amortized to interest expense using the effective interest rate over the life of the note.

Senior Secured Promissory Notes

From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000. The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO. In total, the principal of the Notes is convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note.

As of December 31, 2012, the Company had not repaid the Notes in full and as a result the Company was required to pay each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender’s Notes as of December 31, 2012. The additional interest was accrued on a monthly basis during the year.

In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share. The warrants expire in 5 years. The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique. The total direct costs of approximately $47,800 were recorded as deferred financing costs and were amortized over the term of the Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.

During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock. The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000. In conjunction with this exchange approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation. Included in this total are 532,260 shares representing the Chief Executive Officer’s conversion of his Note. This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the six months ended June 30, 2013.

Line of Credit

On May 17, 2013, the Company and Bank of America, N.A. (the “Lender”) entered into a Loan Agreement (the “Loan Agreement”). The Loan Agreement provides the Company with a secured revolving line of credit (the “Revolving Line of Credit”) of up to $3,000,000, and includes a sub-limit of up to $1,000,000 for the issuance of letters of credit. The Revolving Line of Credit is secured by the Company's accounts receivable and inventory. The Company intends to utilize the Revolving Line of Credit for general corporate purposes. As of the date of this filing, the Company has not made any draws under the Revolving Line of Credit.

Accrued interest with respect to principal amounts outstanding under the Loan Agreement is payable in arrears on a monthly basis calculated at the rate of LIBOR plus two percent (2%). The principal amount outstanding under the Loan Agreement and any accrued and unpaid interest is due no later than May 1, 2014, and the Revolving Line of Credit is subject to certain prepayment penalties upon early termination of the Revolving Line of Credit. The Loan Agreement is subject to renewal by the Lender at the end of the term.

The Loan Agreement contains covenants that limit under certain circumstances the ability of the Company to, among other things, merge with or acquire other entities, incur new liens, incur additional indebtedness, sell assets outside of the ordinary course of business, make loans, advances or other extensions of credit or engage in any business activities substantially different from the Company's present business without the Lender's consent. The Loan Agreement also requires the Company to maintain certain financial covenants, including a minimum funded debt to adjusted EBITDA ratio and a minimum fixed charge coverage ratio. The Company is in compliance with these covenants.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Net Income (loss) Per Share

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Net Income (loss) Per Share

Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method. For all periods presented, diluted net loss per share is the same as basic net loss per share, as the inclusion of equivalent shares from outstanding common stock options, warrants and convertible debt would be anti-dilutive.

The following table sets forth the computation of basic and diluted net loss per share:



	Three months ended June 30,						Six months ended June 30,
	2013			2012			2013			2012
Net income (loss)	$	(757,389	)	$	(744,069	)	$	(2,377,797	)	$	(1,837,721	)
Denominator for basic earnings per share - weighted average shares	95,988,100			79,952,542			94,599,406			77,416,073
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	—			—			—			—
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	95,988,100			79,952,542			94,599,406			77,416,073
Income (loss) per common share - basic and diluted	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.02	)

(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:



	Six months ended June 30,
	2013	2012
Outstanding Stock Options	15,917,272	12,794,250
Outstanding Warrants	2,132,002	7,763,817
Convertible Debt, promissory notes	—	5,186,933
Convertible Line of Credit with Related Party	—	1,375,137
Convertible Debt, Acquisition	—	1,069,808
	18,049,274	28,189,945

Equity

6 Months Ended

Jun. 30, 2013

Equity [Abstract]

Equity

Stock Incentive Plans

The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at June 30, 2013 totaled 375,000. On March 6, 2013, the Board of Directors approved 6,000,000 additional shares to be made available under the 2006 Plan, bringing the maximum number of shares of common stock which can be issued under the 2006 Plan to 22,500,000 at June 30, 2013. The shareholders approved the increase on May 9, 2013.

Activity with respect to the stock options is summarized as follows:



	Number of Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2013	13,614,135		$	1.42
Granted	3,024,500		5.09
Exercised	(489,197	)	1.11
Unvested options forfeited	(179,167	)	3.82
Vested options expired	(52,999	)	1.11
Outstanding at June 30, 2013	15,917,272		2.10		7.9	$	78,906,155
Vested at June 30, 2013	7,044,063		1.12		6.5	$	41,809,325
Vested or expected to vest at June 30, 2013 (a)	15,576,624		$	2.10	7.9	$	77,742,045


(a)	Includes forfeiture adjusted unvested shares.

The intrinsic value of the options exercised during the six months ended June 30, 2013, was approximately $2,345,000.

Following is a summary of stock options outstanding and exercisable at June 30, 2013:



	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price		Number Exercisable	Weighted- Average Exercise Price
$0.50 - $0.76	2,169,500	4.8	$	0.67	2,169,500	$	0.67
$0.87 - $1.35	6,814,572	8.1	1.19		3,356,198	1.18
$1.40 - $2.29	1,816,700	6.4	1.63		1,518,365	1.65
$2.33 - $3.75	2,164,500	9.2	2.75		—	—
$3.95 - $6.53	2,804,000	9.7	5.00		—	—
$6.60 - $6.75	148,000	9.9	6.61		—	—
	15,917,272	7.9	$	2.10	7,044,063	$	1.12

Total unrecognized compensation expense related to granted stock options at June 30, 2013, was approximately $11,717,000 and is expected to be recognized over a weighted-average period of 2.4 years.

The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options. The term of employee options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The term for non-employee options is generally based upon the contractual term of the option. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:



	Six months ended June 30,
	2013	2012
Expected volatility	62.15-64.27%	57.3 - 57.6%
Expected life (in years)	5.5 - 6	6
Expected dividend yield	—	—
Risk-free interest rate	0.85-1.13%	1.48-2.24%

The weighted-average grant date fair value for options granted during the six months ended June 30, 2013 was approximately $2.95 .

During the first six months of 2013, the Company granted 280,000 shares of restricted stock with a weighted-average grant date fair value of $5.23 which vest over a 1 to 3 year period. As of June 30, 2013, there was approximately $1,267,000 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.5 years.

For the three and six months ended June 30, 2013 and 2012, the Company recognized stock-based compensation as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Cost of products sold	$	72,669	$	29,479	$	122,831	$	53,489
Research and development	122,789		75,610		198,767		147,130
Selling, general and administrative	1,306,989		480,126		2,165,641		885,581
	$	1,502,447	$	585,215	$	2,487,239	$	1,086,200

Warrants

The Company grants common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long term equity capital to the Company and as additional compensation to consultants and advisors. The warrants are granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants have been issued for terms of five years.

Following is a summary of the warrant activity for the six months ended June 30, 2013:



	Number of Warrants		Weighted- Average Exercise Price per Warrant
Warrants outstanding at January 1, 2013	3,129,168		$	1.04
Warrants exercised:
Contingent warrants related to private placement of common stock	(62,500	)	0.01
Callable warrants	(266,666	)	1.50
Other	(668,000	)	1.15
Warrants outstanding at June 30, 2013	2,132,002		$	0.98

Warrants may be exercised in whole or in part by:


•	notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or

•

election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.

These warrants are not mandatorily redeemable, and do not obligate the Company to repurchase its equity shares by transferring assets or issuing a variable number of shares.

The warrants require that the Company deliver shares as part of a physical settlement or a net-share settlement, at the option of the holder, and do not provide for a net-cash settlement.

All of our warrants are classified as equity as of June 30, 2013 and December 31, 2012.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income taxes	6 Months Ended
Income taxes	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The Company has incurred net losses since its inception, and therefore, no current income tax liabilities have been incurred for the periods presented. However, the Company does have tax obligations in certain states. This expense and related liability is included in the accompanying financial statements as income tax provision and accounts payable, respectively. The amount of federal operating loss carryforwards was approximately $43,100,000 at June 30, 2013. A valuation allowance is recorded to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that a portion or none of the deferred tax assets will be realized. After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management has determined that a full valuation allowance is necessary as of June 30, 2013. Additionally, the Company has various tax credit carryforwards of approximately $1,400,000 as of June 30, 2013.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Supplemental disclosure of cash flow and non-cash investing and financing activities

6 Months Ended

Jun. 30, 2013

Supplemental Cash Flow Elements [Abstract]

Supplemental disclosure of cash flow and non-cash investing and financing activities


	Supplemental disclosure of cash flow and non-cash investing and financing activities:

Selected cash payments, receipts, and noncash activities are as follows:



	Six Months Ended June 30,
	2013		2012
Cash paid for interest	$	17,662	$	5,435
Income taxes paid	50,275		—
Purchases of property, plant and equipment financed capital leases	107,259		72,302
Stock issuance of 167,086 shares in lieu of Director's fees	—		184,653
Deferred financing costs	27,236		9,537
Beneficial conversion related to line of credit with related party	—		514,456
Stock issuance in connection with Earn-Out Liability of 1,174, 915 shares for 2013 and
2,632,576 shares for 2012	5,792,330		3,185,223
Stock issuance of 5,272,004 shares in exchange for convertible debt	5,272,004		—
Company issued shares of 167,183 for cashless exercise	—		167
Tenant improvement incentive, net of amortization of $28,895	967,971		—

Contractual Commitments

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Contractual Commitments

Contractual Commitments and Contingencies

Contractual Commitments

In addition to the Capital Leases noted above, the Company has entered into operating lease agreements for facility space and equipment. The estimated annual lease payments are as follows:



12-month period ended June 30
2014	$	837,406
2015	1,122,322
2016	1,319,454
2017	1,359,514
Thereafter	2,237,443
	$	6,876,139

Letters of Credit

As a condition of the leases for the Company's facility space we are obligated under standby letters of credit in the amount of approximately $550,000. These obligations decrease in value at various times over the lives of the leases.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Subsequent Events

6 Months Ended

Jun. 30, 2013

Subsequent Events [Abstract]

Subsequent Events


	Subsequent Events

On July 3, 2013, the Company filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission ("SEC"). This registration will enable the Company to offer and sell to the public from time to time in one or more offerings, up to $100,500,000 of common and preferred stock, warrants, units or any combination thereof. In addition, under the shelf registration certain MiMedx shareholders may offer for resale to the public from time to time in one or more offerings up to 7,500,000 shares of MiMedx common stock.

The terms of any securities offered under the registration statement, and the intended use of the net proceeds resulting therefrom, will be established at the times of the offerings and will be described in prospectus supplements filed with the SEC at the times of the offerings.

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2013
Accounting Policies [Abstract]
Reclassifications	Reclassifications Certain items previously reported in financial statement captions have been reclassified to conform to the current financial statement presentation. These reclassifications did not affect total assets, total liabilities, and stockholders’ equity.
Use of estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable	Accounts Receivable Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. The Company has $44,000 and $49,000 in the allowance for doubtful accounts as of June 30, 2013 and December 31, 2012, respectively. Actual customer collections could differ from estimates. The approximate provision during the six months ended June 30, 2013 was $27,000, and there were approximately $32,000 of write–offs during the same period.
Inventories	Inventories Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
Revenue Recognition	Revenue Recognition The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilized distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The Company recorded approximately $281,000 and $107,000 for net sales returns provisions for the three months ended June 30, 2013 and 2012, respectively, and there were approximately $231,000 and $26,000 of charges against the provision during the three months ended June 30, 2013 and 2012, respectively. The Company recorded approximately $471,000 and $146,000 for net sales returns provisions for the six months ended June 30, 2013 and 2012, respectively, and there were approximately $397,000 and $26,000 of charges against the provision during the six months ended June 30, 2013 and 2012, respectively.
Patent Costs	Patent Costs The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company considers the applicability and impact of all ASUs. For the six months ended June 30, 2013 and through the date of this report, all ASUs issued, effective and not yet effective, were assessed and determined to be either not applicable or are expected to have minimal impact on our financial position or results of operations.

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4492-108314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2126999

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4556-108314

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 81-1
-Paragraph 69-75
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Paragraph 3, 5-10, 15, 16, 17
-Chapter 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 206
-Paragraph b
-Subparagraph i, ii
-Chapter 2

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 9
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5

+ Details

- Definition

Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2196772

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2196816

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3-5
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 01-6
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 92-5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 114
-Paragraph 20
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventories (Tables)

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Inventory

Inventories consisted of the following items as of June 30, 2013 and December 31, 2012:



	June 30, 2013			December 31, 2012
Raw materials	$	270,441		$	233,747
Work in process	2,765,802			1,598,537
Finished goods	1,425,996			1,349,121
	4,462,239			3,181,405
Reserve for obsolescence	(241,955		)	(158,621		)
Inventory, net	$	4,220,284		$	3,022,784

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2013

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consist of the following as of June 30, 2013 and December 31, 2012:



	June 30, 2013			December 31, 2012
Leasehold improvements	$	2,147,775		$	1,022,230
Lab and clean room equipment	1,901,219			1,887,645
Furniture and office equipment	903,433			431,563
Construction in progress	556,093			10,027
	5,508,520			3,351,465
Less accumulated depreciation	(2,517,774		)	(2,279,840		)
	$	2,990,746		$	1,071,625

Intangible Assets and Royalty Agreement (Tables)

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Activity

Intangible assets activity is summarized as follows:



	June 30, 2013								December 31, 2012
	Weighted Average Amortization Lives	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Impairment Adjustment			Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization:
License-Shriners Hsp for Children & USF Research (a)	10 years	$	996,000	$	(637,433	)	$	358,567	$	996,000	$	—		$	(587,633	)	$	408,367
License - SaluMedica LLC Spine Repair (b)	10 years	1,547,324		(1,547,324		)	—		2,399,000		(851,676		)	(1,547,324		)	—
License - Polyvinyl Alcohol Cryogel (c)	10 years	1,720,181		(1,287,824		)	432,357		2,667,000		(946,819		)	(1,223,561		)	496,620
Customer Relationships (d)	14 years	3,520,000		(628,572		)	2,891,428		3,520,000		—			(502,857		)	3,017,143
Supplier Relationships (d)	14 years	241,000		(43,036		)	197,964		241,000		—			(34,428		)	206,572
Patents & Know-How (d)	14 years	5,530,000		(987,500		)	4,542,500		5,530,000		—			(790,000		)	4,740,000
Micronized Processing Know-How (d)	14 years	2,160,000		(231,428		)	1,928,572		2,160,000		—			(154,286		)	2,005,714
Licenses/Permits (d)	3 years	13,000		(10,833		)	2,167		13,000		—			(8,667		)	4,333
Patent Application Cost ( e )	17 years	342,695		(5,040		)	337,655		—		—			—			—
		16,070,200		(5,378,990		)	10,691,210		17,526,000		(1,798,495		)	(4,848,756		)	10,878,749
Intangible assets not subject to amortization:
Trade Names/Trademarks (d)	indefinite	1,008,000		—			1,008,000		1,008,000		—			—			1,008,000
In-process Research & Development-Other (d)	indefinite	25,000		—			25,000		25,000		—			—			25,000
		$	17,103,200	$	(5,378,990	)	$	11,724,210	$	18,559,000	$	(1,798,495	)	$	(4,848,756	)	$	11,911,749

(a)


(b)	License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value.

(c)


(d)	On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.

(e) Capitalized external legal and other registration costs in connection with internally developed tissue based patents.

Estimated future amortization expense for intangible assets

Expected future amortization of intangible assets is as follows:



	Estimated Amortization Expense
Year ending December 31,	Estimated Amortization Expense
2013 (a)	$	535,266
2014	1,066,205
2015	1,044,151
2016	997,156
2017	906,960
Thereafter	6,141,472
	$	10,691,210


(a)	Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after June 30, 2013.

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Long-term Debt

The following table summarizes our long-term debt:



	June 30, 2013		December 31, 2012
$5M Convertible Senior Secured Promissory Notes including interest at 5% per annum payable quarterly through December 31, 2013, and an additional one time 5% interest charge payable on January 15, 2013 if not repaid by December 31, 2012, collateralized by a first priority lien shared equally with holder of the Convertible Line of Credit with Related Party in all of the patents and intellectual property owned by the Company subordinated to the Convertible Debt related to acquisition for Surgical Biologics intellectual property until repaid. (a)	$	—	$	5,313,645
Total debt	—		5,313,645
Less unamortized debt discount	—		(1,301,203		)
Less current portion	—		—
Long-term portion	$	—	$	4,012,442

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Net Income (loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share:



	Three months ended June 30,						Six months ended June 30,
	2013			2012			2013			2012
Net income (loss)	$	(757,389	)	$	(744,069	)	$	(2,377,797	)	$	(1,837,721	)
Denominator for basic earnings per share - weighted average shares	95,988,100			79,952,542			94,599,406			77,416,073
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	—			—			—			—
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	95,988,100			79,952,542			94,599,406			77,416,073
Income (loss) per common share - basic and diluted	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.02	)

(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows

Summary of Antidilutive Securities

(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:



	Six months ended June 30,
	2013	2012
Outstanding Stock Options	15,917,272	12,794,250
Outstanding Warrants	2,132,002	7,763,817
Convertible Debt, promissory notes	—	5,186,933
Convertible Line of Credit with Related Party	—	1,375,137
Convertible Debt, Acquisition	—	1,069,808
	18,049,274	28,189,945

Equity (Tables)

6 Months Ended

Jun. 30, 2013

Equity [Abstract]

Stock Options Activity

Activity with respect to the stock options is summarized as follows:



	Number of Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2013	13,614,135		$	1.42
Granted	3,024,500		5.09
Exercised	(489,197	)	1.11
Unvested options forfeited	(179,167	)	3.82
Vested options expired	(52,999	)	1.11
Outstanding at June 30, 2013	15,917,272		2.10		7.9	$	78,906,155
Vested at June 30, 2013	7,044,063		1.12		6.5	$	41,809,325
Vested or expected to vest at June 30, 2013 (a)	15,576,624		$	2.10	7.9	$	77,742,045


(a)	Includes forfeiture adjusted unvested shares.

Stock Options Outstanding and Exercisable

Following is a summary of stock options outstanding and exercisable at June 30, 2013:



	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price		Number Exercisable	Weighted- Average Exercise Price
$0.50 - $0.76	2,169,500	4.8	$	0.67	2,169,500	$	0.67
$0.87 - $1.35	6,814,572	8.1	1.19		3,356,198	1.18
$1.40 - $2.29	1,816,700	6.4	1.63		1,518,365	1.65
$2.33 - $3.75	2,164,500	9.2	2.75		—	—
$3.95 - $6.53	2,804,000	9.7	5.00		—	—
$6.60 - $6.75	148,000	9.9	6.61		—	—
	15,917,272	7.9	$	2.10	7,044,063	$	1.12

Fair Value of Options, Valuation Assumptions

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:



	Six months ended June 30,
	2013	2012
Expected volatility	62.15-64.27%	57.3 - 57.6%
Expected life (in years)	5.5 - 6	6
Expected dividend yield	—	—
Risk-free interest rate	0.85-1.13%	1.48-2.24%

Allocation of Share-based Compensation

For the three and six months ended June 30, 2013 and 2012, the Company recognized stock-based compensation as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Cost of products sold	$	72,669	$	29,479	$	122,831	$	53,489
Research and development	122,789		75,610		198,767		147,130
Selling, general and administrative	1,306,989		480,126		2,165,641		885,581
	$	1,502,447	$	585,215	$	2,487,239	$	1,086,200

Summary of Warrants Outstanding

Following is a summary of the warrant activity for the six months ended June 30, 2013:



	Number of Warrants		Weighted- Average Exercise Price per Warrant
Warrants outstanding at January 1, 2013	3,129,168		$	1.04
Warrants exercised:
Contingent warrants related to private placement of common stock	(62,500	)	0.01
Callable warrants	(266,666	)	1.50
Other	(668,000	)	1.15
Warrants outstanding at June 30, 2013	2,132,002		$	0.98

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables)

6 Months Ended

Jun. 30, 2013

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities



	Six Months Ended June 30,
	2013		2012
Cash paid for interest	$	17,662	$	5,435
Income taxes paid	50,275		—
Purchases of property, plant and equipment financed capital leases	107,259		72,302
Stock issuance of 167,086 shares in lieu of Director's fees	—		184,653
Deferred financing costs	27,236		9,537
Beneficial conversion related to line of credit with related party	—		514,456
Stock issuance in connection with Earn-Out Liability of 1,174, 915 shares for 2013 and
2,632,576 shares for 2012	5,792,330		3,185,223
Stock issuance of 5,272,004 shares in exchange for convertible debt	5,272,004		—
Company issued shares of 167,183 for cashless exercise	—		167
Tenant improvement incentive, net of amortization of $28,895	967,971		—

Contractual Commitments (Tables)

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Estimated Annual Lease, Royalty and Employment Agreement Expenses

In addition to the Capital Leases noted above, the Company has entered into operating lease agreements for facility space and equipment. The estimated annual lease payments are as follows:



12-month period ended June 30
2014	$	837,406
2015	1,122,322
2016	1,319,454
2017	1,359,514
Thereafter	2,237,443
	$	6,876,139

Basis of Presentation (Details)	6 Months Ended
Basis of Presentation (Details)	Jun. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments	1

Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Accounts Receivable [Abstract]
Allowance for doubtful accounts	$ 44,000		$ 44,000		$ 49,000
Provision for doubtful accounts			27,000
Accounts receivable charge-offs		$ 0	32,000
Revenue Recognition [Abstract]
Net sales returns provision	281,000	107,000	471,000		146,000
Provision charges	$ 231,000	$ 26,000	397,000		$ 26,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net of accumulated amortization			$ 343,000	$ 0

Liquidity and Management's Plans (Details) - USD ($)	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2011
Liquidity and management's plans [Abstract]
Cash and cash equivalents	$ 4,193,583	$ 6,754,485	$ 2,654,694	$ 4,112,326
Total current assets	21,527,689	18,088,791
Total current liabilities	$ 6,140,679	$ 5,070,772

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventories (Details) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Raw materials	$ 270,441	$ 233,747
Work in process	2,765,802	1,598,537
Finished goods	1,425,996	1,349,121
Gross Inventory	4,462,239	3,181,405
Reserve for obsolescence	(241,955)	(158,621)
Inventory, net	$ 4,220,284	$ 3,022,784

- Definition

The amount of the valuation account as of the balance sheet date which reduces the carrying amount of inventory to net realizable value; takes into consideration such factors as market value, excessive quantities based on expected sales, technological obsolescence, and shrinkage. May also provide for estimated product returns or price concessions pertaining to product cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=6386940&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Paragraph 14
-Chapter 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Paragraph 8, 9, 14
-Chapter 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 9
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5

+ Details

Property and Equipment (Details) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Property and equipment [Line Items]
Property and equipment, gross	$ 5,508,520	$ 3,351,465
Less accumulated depreciation	(2,517,774)	(2,279,840)
Property and equipment, net	2,990,746	1,071,625
Leasehold Improvements [Member]
Property and equipment [Line Items]
Property and equipment, gross	2,147,775	1,022,230
Lab and Clean Room Equipment [Member]
Property and equipment [Line Items]
Property and equipment, gross	1,901,219	1,887,645
Furniture and Office Equipment [Member]
Property and equipment [Line Items]
Property and equipment, gross	903,433	431,563
Construction in Progress [Member]
Property and equipment [Line Items]
Property and equipment, gross	556,093	$ 10,027
Other Liabilities [Member]
Property and equipment [Line Items]
Capital lease obligations	$ 154,000

Intangible Assets and Royalty Agreement (Details) - USD ($)

3 Months Ended

Mar. 31, 2008

Jan. 29, 2007

Jun. 30, 2013

Dec. 31, 2012

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

$ 16,070,200

$ 17,526,000

Accumulated Amortization

(5,378,990)

(4,848,756)

Acquisition price, one-time license fee

$ 100,000

Impairment Adjustment

(1,798,495)

Net carrying value, Total

10,691,210

10,878,749

Shares issued for intangibles (in shares)

1,120,000

Value of shares issued for intangibles

$ 896,000

Maximum time of approval

30 days

Contingent payments to licensor

$ 200,000

Contingent royalty to be paid to licensor (in hundredths)

3.00%

Acquisition price of asset, shares issued (in shares)

400,000

Acquisition of asset, value of shares issued

$ 2,596,000

Number of shares issuable upon meeting certain milestones (in shares)

600,000

Contingent payments to licensor, shares issued (in shares)

100,000

Contingent payment to licensor, value of shares issued

$ 71,000

Indefinite-lived Intangible Assets [Line Items]

Intangible assets, gross carrying value

17,103,200

18,559,000

Impairment Adjustment

(1,798,495)

Accumulated Amortization

(5,378,990)

(4,848,756)

Intangible assets, net carrying value

11,724,210

11,911,749

Estimated future amortization expense [Abstract]

2013

^[1]

535,266

1,066,205

1,044,151

997,156

906,960

$ 6,141,472

Trade Names and Trademarks [Member]

Indefinite-lived Intangible Assets [Line Items]

Weighted average useful life Indefinite lived

^[2]

indefinite

Gross Carrying Value

^[2]

$ 1,008,000

1,008,000

Accumulated Amortization

^[2]

Net Carrying Value

^[2]

$ 1,008,000

1,008,000

In Process Research and Development, Other [Member]

Indefinite-lived Intangible Assets [Line Items]

Weighted average useful life Indefinite lived

^[2]

indefinite

Gross Carrying Value

^[2]

$ 25,000

25,000

Accumulated Amortization

^[2]

Net Carrying Value

^[2]

$ 25,000

25,000

License-Shriners Hsp for Children & USF Research [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[3]

10 years

Gross Carrying Value

^[3]

$ 996,000

996,000

Accumulated Amortization

^[3]

(637,433)

(587,633)

Net carrying value, Total

^[3]

$ 358,567

408,367

License - SaluMedica LLC Spine Repair [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[4]

10 years

Gross Carrying Value

^[4]

$ 1,547,324

2,399,000

Accumulated Amortization

^[4]

(1,547,324)

Impairment Adjustment

^[4]

(851,676)

Net carrying value, Total

^[4]

$ 0

License - Polyvinyl Alcohol Cryogel [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[5]

10 years

Gross Carrying Value

^[5]

$ 1,720,181

2,667,000

Accumulated Amortization

^[5]

(1,287,824)

(1,223,561)

Impairment Adjustment

^[5]

(946,819)

Net carrying value, Total

^[5]

$ 432,357

496,620

Customer Relationships [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[2]

14 years

Gross Carrying Value

^[2]

$ 3,520,000

3,520,000

Accumulated Amortization

^[2]

(628,572)

(502,857)

Net carrying value, Total

^[2]

$ 2,891,428

3,017,143

Supplier Relationships [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[2]

14 years

Gross Carrying Value

^[2]

$ 241,000

241,000

Accumulated Amortization

^[2]

(43,036)

(34,428)

Net carrying value, Total

^[2]

$ 197,964

206,572

Patents and Know-How [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[2]

14 years

Gross Carrying Value

^[2]

$ 5,530,000

5,530,000

Accumulated Amortization

^[2]

(987,500)

(790,000)

Net carrying value, Total

^[2]

$ 4,542,500

4,740,000

Micronized Processing Know-How [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[2]

14 years

Gross Carrying Value

^[2]

$ 2,160,000

2,160,000

Accumulated Amortization

^[2]

(231,428)

(154,286)

Net carrying value, Total

^[2]

$ 1,928,572

2,005,714

Licenses and Permits [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[2]

3 years

Gross Carrying Value

^[2]

$ 13,000

13,000

Accumulated Amortization

^[2]

(10,833)

(8,667)

Net carrying value, Total

^[2]

$ 2,167

4,333

Patent Application Cost [Member]

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[6]

17 years

Gross Carrying Value

^[6]

$ 342,695

Accumulated Amortization

^[6]

(5,040)

Net carrying value, Total

^[6]

$ 337,655

$ 0

[1]	Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after June 30, 2013.
[2]	On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development
[3]	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date). Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products
[4]	License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value
[5]	On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol hydrogel. The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date). The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales. On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement. As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000. In September 2012, the cost of the license was deemed to be impaired and reduced to its fair value. At June 30, 2013 and December 31, 2012, there are no additional amounts accrued for this obligation due to its contingent nature
[6]	Capitalized external legal and other registration costs in connection with internally developed tissue based patents.

Long-Term Debt (Details) - USD ($)

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jul. 03, 2012

Jan. 29, 2007

Jul. 31, 2012

Feb. 28, 2013

Jun. 30, 2013

Dec. 31, 2011

May 17, 2013

Dec. 31, 2012

Debt Instrument [Line Items]

Total debt

$ 0

$ 5,313,645

Less unamortized debt discount

1,301,203

Less current portion

Long-term portion

$ 0

4,012,442

Annual interest rate (in hundredths)

5.00%

Placement fee, warrants issued (in shares)

1,120,000

Warrants term

5 years

5% Convertible Senior Secured Promissory Note [Member]

Debt Instrument [Line Items]

Total debt

^[1]

$ 0

$ 5,313,645

Annual interest rate (in hundredths)

5.00%

Maturity date

Dec. 31, 2013

Additional interest payment (in hundredths)

5.00%

Warrant exercise price (in dollars per share)

$ 1.09

Proceeds from issuance of debt

$ 5,000,000

Convertible debt, shares issuable if converted (in shares)

5,000,000

Unpaid interest to be considered for conversion in to shares of common stock (in dollars per share)

$ 1.00

Placement fee

$ 32,800

Placement fee, warrants issued (in shares)

42,400

Warrants term

5 years

Fair value of placement fee warrants

$ 15,000

Direct costs of sale of notes

$ 47,800

5% Convertible Senior Secured Promissory Note [Member] | First Contingent Warrants [Member]

Debt Instrument [Line Items]

Percentage of equity securities to be sold for conversion of notes (in hundredths)

25.00%

Warrant exercise price (in dollars per share)

$ 0.01

Warrants vested (in shares)

1,250,000

Beneficial Conversion Feature Value Related To Convertible Debt Issued With Regard To Senior Secured Promissory Notes

$ 2,278,052

5% Convertible Senior Secured Promissory Note [Member] | Second Contingent Warrants [Member]

Debt Instrument [Line Items]

Percentage of equity securities to be sold for conversion of notes (in hundredths)

25.00%

Warrant exercise price (in dollars per share)

$ 0.01

Warrants voided (in shares)

1,250,000

Closing trading price of Company stock (in dollars per share)

$ 1.75

Number of consecutive trading days

10 days

5% Convertible Senior Secured Promissory Note [Member] | Chairman and CEO [Member]

Debt Instrument [Line Items]

Proceeds from issuance of debt

$ 500,000

Loan Agreement [Member]

Debt Instrument [Line Items]

Less unamortized debt discount

$ 1,328,000

Debt Conversion, Converted Instrument, Amount

$ 5,272,000

Convertible secured promissory note to common stock (in shares)

5,272,000

532,260

Revolving Credit Facility [Member] | Bank of America [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 3,000,000

Letter of Credit [Member] | Bank of America [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 1,000,000

London Interbank Offered Rate (LIBOR) [Member] | Loan Agreement [Member]

Debt Instrument [Line Items]

Annual interest rate (in hundredths)

2.00%

[1]

Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. On December 31, 2011, a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company's share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052 which was recorded as a debt discount and was amortized to interest expense using the effective interest rate over the life of the note.

Net Income (loss) Per Share (Details) - USD ($)

3 Months Ended

6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Computation of basic and diluted net loss per share [Abstract]

Net income (loss)

$ (757,389)

$ (744,069)

$ (2,377,797)

$ (1,837,721)

Denominator for basic earnings per share - weighted average shares (in shares)

95,988,100

79,952,542

94,599,406

77,416,073

Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares)

^[1]

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares)

95,988,100

79,952,542

94,599,406

77,416,073

Income (loss) per common share - basic and diluted (in dollars per share)

$ (0.01)

$ (0.03)

$ (0.02)

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)

18,049,274

28,189,945

Outstanding Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)

15,917,272

12,794,250

Outstanding Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)

2,132,002

7,763,817

Convertible Debt, Promissory Notes [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)

5,186,933

Revolving Credit Facility [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)

1,375,137

Convertible Debt, Acquisition [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)

1,069,808

[1]	Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:

Equity (Details)	3 Months Ended		6 Months Ended
Equity (Details)	Jun. 30, 2013 USD ($) $ / shares $ / Unit shares	Jun. 30, 2012 USD ($)	Jun. 30, 2013 USD ($) $ / shares $ / Unit shares	Jun. 30, 2012 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share-based compensation plans	3
Outstanding assumed options (in shares) \| shares	375,000		375,000
Additional shares authorized by Board of Directors (in shares) \| shares	6,000,000
Shares authorized (in shares) \| shares	22,500,000		22,500,000
Total unrecognized compensation expense \| $	$ 11,717,000		$ 11,717,000
Number of shares [Roll forward]
Outstanding, beginning of period (in shares) \| shares			13,614,135
Granted (in shares) \| shares			3,024,500
Exercised (in shares) \| shares			(489,197)
Unvested options forfeited (in shares) \| shares			(179,167)
Vested options expired (in shares) \| shares			(52,999)
Outstanding, end of period (in shares) \| shares	15,917,272		15,917,272
Vested at end of period (in shares) \| shares	7,044,063		7,044,063
Exercisable options, vested and expected to vest (in shares) \| shares	15,576,624		15,576,624
Weighted-Average Exercise Price [Roll forward]
Outstanding, weighted average exercise price, beginning of period (in dollars per share)			$ 1.42
Granted, weighted average exercise price (in dollars per share)			5.09
Exercised, weighted average exercise price (in dollars per share)			1.11
Unvested options forfeited weighted-average exercise price (in dollars per share)			3.82
Vested options expired weighted-average exercise price (in dollars per share)			1.11
Outstanding, weighted average exercise price, end of period (in dollars per share)	$ 2.10		2.10
Vested at end of period weighted average exercise price (in dollars per share)	1.12		1.12
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 2.10		$ 2.10
Stock options, additional disclosures [Abstract]
Vested at end of period weighted average remaining contractual term			6 years 6 months
Vested and expected to vest, weighted average remaining contractual term			7 years 10 months 24 days
Outstanding intrinsic value \| $	$ 78,906,155		$ 78,906,155
Vested at end of period aggregate intrinsic value \| $	41,809,325		41,809,325
Vested and expected to vest, aggregate intrinsic value \| $	77,742,045		$ 77,742,045
Exercised options, intrinsic value \| $	$ 2,345,000
Number of outstanding options (in shares) \| shares	15,917,272		15,917,272
Outstanding Options, weighted average remaining contractual term	7 years 10 months 24 days		7 years 10 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 2.10		$ 2.10
Number of exercisable options (in shares) \| shares	7,044,063		7,044,063
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.12		$ 1.12
Fair value options valuation assumptions [Abstract]
Expected life				6 years
Expected dividend yield (in hundredths)			0.00%	0.00%
Risk-free interest rate, minimum (in hundredths)			1.13%	2.24%
Risk-free interest rate, maximum (in hundredths)			0.85%	1.48%
Share-based Compensation [Abstract]
Share-based compensation expense \| $	$ 1,502,447	$ 585,215	$ 2,487,239	$ 1,086,200
Weighted-average grant date fair value for options granted during the period (in dollars per share)	$ 2.95
Warrants, term	5 years
Warrants [Member]
Warrants, Number of Warrants [Roll Forward]
Warrants outstanding, beginning of period (in shares) \| shares			3,129,168
Warrants outstanding, end of period (in shares) \| shares	2,132,002		2,132,002
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants outstanding, beginning of period (in dollars per share) \| $ / Unit			1.04
Warrants outstanding, end of period (in dollars per share) \| $ / Unit	0.98		0.98
Contingent Warrants Related to Private Placement of Common Stock [Member] \| Warrants [Member]
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares) \| shares			(62,500)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / Unit			0.01
Callable Warrants [Member] \| Warrants [Member]
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares) \| shares			(266,666)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / Unit			1.50
Other [Member] \| Warrants [Member]
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares) \| shares			(668,000)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / Unit			1.15
Cost of Products Sold [Member]
Share-based Compensation [Abstract]
Share-based compensation expense \| $	$ 72,669	29,479	$ 122,831	53,489
Research and Development [Member]
Share-based Compensation [Abstract]
Share-based compensation expense \| $	122,789	75,610	198,767	147,130
Selling, General and Administrative [Member]
Share-based Compensation [Abstract]
Share-based compensation expense \| $	$ 1,306,989	$ 480,126	$ 2,165,641	$ 885,581
$0.50-$0.76 [Member]
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)	$ 0.50
Exercise Price Range, upper range limit (in dollars per share)	$ 0.76
Number of outstanding options (in shares) \| shares	2,169,500		2,169,500
Outstanding Options, weighted average remaining contractual term	4 years 9 months 18 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 0.67		$ 0.67
Number of exercisable options (in shares) \| shares	2,169,500		2,169,500
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0.67		$ 0.67
$0.87-$1.35 [Member]
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)	0.87
Exercise Price Range, upper range limit (in dollars per share)	$ 1.35
Number of outstanding options (in shares) \| shares	6,814,572		6,814,572
Outstanding Options, weighted average remaining contractual term	8 years 1 month 6 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 1.19		$ 1.19
Number of exercisable options (in shares) \| shares	3,356,198		3,356,198
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.18		$ 1.18
$1.40-$2.29 [Member]
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)	1.40
Exercise Price Range, upper range limit (in dollars per share)	$ 2.29
Number of outstanding options (in shares) \| shares	1,816,700		1,816,700
Outstanding Options, weighted average remaining contractual term	6 years 4 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 1.63		$ 1.63
Number of exercisable options (in shares) \| shares	1,518,365		1,518,365
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.65		$ 1.65
$2.33-$3.75 [Member]
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)	2.33
Exercise Price Range, upper range limit (in dollars per share)	$ 3.75
Number of outstanding options (in shares) \| shares	2,164,500		2,164,500
Outstanding Options, weighted average remaining contractual term	9 years 2 months 12 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 2.75		$ 2.75
Number of exercisable options (in shares) \| shares	0		0
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0		$ 0
$3.95-$6.53 [Member]
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)	3.95
Exercise Price Range, upper range limit (in dollars per share)	$ 6.53
Number of outstanding options (in shares) \| shares	2,804,000		2,804,000
Outstanding Options, weighted average remaining contractual term	9 years 8 months 12 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 5.00		$ 5.00
Number of exercisable options (in shares) \| shares	0		0
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0		$ 0
$6.60-$6.75 [Member]
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)	6.6
Exercise Price Range, upper range limit (in dollars per share)	$ 6.75
Number of outstanding options (in shares) \| shares	148,000		148,000
Outstanding Options, weighted average remaining contractual term	9 years 10 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 6.61		$ 6.61
Number of exercisable options (in shares) \| shares	0		0
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0		$ 0
Maximum [Member]
Fair value options valuation assumptions [Abstract]
Expected volatility (in hundredths)			64.27%	57.60%
Expected life			6 years
Minimum [Member]
Fair value options valuation assumptions [Abstract]
Expected volatility (in hundredths)			62.15%	57.30%
Expected life			5 years 6 months
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expenses expected to be recognized over a weighted-average period	2 years 4 months 24 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expenses expected to be recognized over a weighted-average period	2 years 6 months
Number of shares granted (in shares) \| shares	280,000
Weighted-average grant date fair value (in dollars per share)	$ 5.23
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock \| $	$ 1,267,000		$ 1,267,000
Restricted Stock [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year

Income taxes (Details) $ in Millions	Jun. 30, 2013 USD ($)
Research Tax Credit [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	$ 1.4
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 43.1

Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) - USD ($)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]
Cash paid for interest	$ 17,662	$ 5,435
Income taxes paid	50,275	0
Purchases of property, plant and equipment financed via capital leases	107,259	72,302
Stock issuance of 167,086 shares in lieu of Director's fees	0	$ 184,653
Stock Issuance in lieu of Director's fees (in shares)		167,086
Deferred financing costs	27,236	$ 9,537
Beneficial conversion related to line of credit with related party	0	514,456
Stock issuance in connection with Earn-Out Liability of 1,174, 915 shares for 2013 and 2,632,576 shares in 2012	$ 5,792,330	$ 3,185,223
Stock issued for earn-out liability (in shares)	1,174,915	2,632,576
Stock issuance in exchange for convertible debt	$ 5,272,004	$ 0
Stock issued for convertible debt (in shares)	5,272,004
Cashless exercise of warrants	$ 0	$ 167
Shares issued for Cashless Exercise (in shares)		167,183
Tenant improvement incentive	967,971	$ 0
Amortization of tenant improvements	$ 28,895

Contractual Commitments (Details)	Jun. 30, 2013 USD ($)
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
2014	$ 837,406
2015	1,122,322
2016	1,319,454
2017	1,359,514
Thereafter	2,237,443
Total Contractual commitments	6,876,139
Standby Letters of Credit [Member]
Loss Contingencies [Line Items]
Standby letters of credit	$ 550,000

Subsequent Events (Details) - Subsequent Event [Member]	Jul. 03, 2013 USD ($) shares
Subsequent Event [Line Items]
Proceeds from Issuance Initial Public Offering \| $	$ 100,500,000
Common Stock [Member]
Subsequent Event [Line Items]
Shareholders, Resale to the Public, Shares \| shares	7,500,000